October 2014
October 27, 2014
Photo Release — Cellular Dynamics Awarded $1.2 Million NEI Contract for Developing Patient-Derived Stem Cells in Gear-Up for Age-Related Macular Degeneration TrialDownload PDF
MADISON, Wis., Oct. 27, 2014 (GLOBE NEWSWIRE) — Cellular Dynamics International (CDI) (Nasdaq:ICEL), today announced that the National Eye Institute (NEI), a division of the National Institutes of Health (NIH), awarded the company a $1.2 million contract to manufacture clinically compatible induced pluripotent stem cells (iPSCs) and iPSC-derived human retinal pigment epithelial (RPE) cells. These…
October 21, 2014
Cellular Dynamics to Present at the 2014 Medical Innovation SummitDownload PDF
MADISON, Wis., Oct. 21, 2014 (GLOBE NEWSWIRE) — Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL) today announced that Chief Executive Officer Bob Palay will present at the Cleveland Clinic’s 2014 Medical Innovation Summit to be held October 27-29 in Cleveland. The following are specific details regarding CDI’s presentation: Date: Tuesday, October 28, 2014 Time: 2:15 pm…
October 1, 2014
Cellular Dynamics to Present at 2014 Stem Cell Meeting on the MesaDownload PDF
MADISON, Wis., Oct. 1, 2014 (GLOBE NEWSWIRE) — Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL) today announced that Chief Executive Officer Bob Palay will present at the 4th Annual Partnering Forum, part of the 2014 Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA. Stem Cell Meeting on the Mesa…
August 2014
August 28, 2014
Cellular Dynamics Awarded U.S. Patent Covering Automated Production of All Human Pluripotent Stem CellsDownload PDF
Patent Strengthens CDI’s Position as Leading Manufacturer of Human Cells for Research and Clinical Applications MADISON, Wis., Aug. 28, 2014 (GLOBE NEWSWIRE) — Cellular Dynamics International (CDI) (Nasdaq:ICEL) today announced that the U.S. Patent and Trademark Office (PTO) awarded the company Patent No. 8,815,585 on the automated production of human pluripotent stem cells, including induced…
July 2014
July 9, 2014
Cellular Dynamics Awarded Patents Covering Derivation of Pluripotent Stem Cells From Fresh or Banked Human Blood SamplesDownload PDF
Patents Secure CDI’s Position as Leading Manufacturer of Human Cells From Most Common, Easily Accessible Donor Source for Research, Drug Discovery and Regenerative Medicine MADISON, Wis., July 9, 2014 (GLOBE NEWSWIRE) — Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL), today announced that the U.S. Patent and Trademark Office (PTO) awarded the company three patents on the…
April 2014
April 30, 2014
Cellular Dynamics Announces Launch of iCell(R) DopaNeurons, Neural Floor Plate-Derived Midbrain Dopaminergic NeuronsDownload PDF
Cells Provide a More Relevant In Vitro Model for Neurological Disorders, Including Parkinson’s Disease and Schizophrenia MADISON, Wis., April 30, 2014 (GLOBE NEWSWIRE) — Cellular Dynamics International, Inc. (CDI) (Nasdaq:ICEL) today announced the launch of iCell® DopaNeurons, the company’s neural floor plate-derived midbrain dopaminergic neurons generated from human induced pluripotent stem cells (iPSCs). Key points:…
January 2014
January 8, 2014
Cellular Dynamics Signs Agreement With Nestle Institute of Health Sciences to Supply iCell® and MyCell® Products for Nutritional ResearchDownload PDF
MADISON, Wis., Jan. 8, 2014 (GLOBE NEWSWIRE) — Cellular Dynamics International (CDI) (Nasdaq:ICEL) today announced signing a long-term supply agreement with the Nestlé Institute of Health Sciences SA (NIHS). Terms of the agreement were not disclosed. CDI’s iCell® product line includes cardiomyocytes, neurons, hepatocytes, and endothelial cells, with numerous other cell types in development. The…
December 2013
December 9, 2013
The Hamner Institutes and Cellular Dynamics Collaborate to Develop In Vitro Assays Using Human iPS Cell-Derived HepatocytesDownload PDF
Collaboration Will Accelerate Innovative Toxicity Testing Research RESEARCH TRIANGLE PARK, N.C. and MADISON, Wis., Dec. 9, 2013 (GLOBE NEWSWIRE) — The Hamner Institutes for Health Sciences today announced a collaborative agreement with Cellular Dynamics International (CDI) to develop predictive in vitro screening assays for chemical, environmental and pharmaceutical toxicology assessments that utilize CDI’s human induced…
December 4, 2013
Jain Foundation Signs Agreement With Cellular Dynamics to Create iPSC Lines From Patients With Muscular DystrophiesDownload PDF
Patient-Derived iPSC Lines Will be Used as Disease Models for Basic Research and Drug Discovery SEATTLE and MADISON, Wis., Dec. 4, 2013 (GLOBE NEWSWIRE) — The Jain Foundation, a non-profit organization whose mission is to cure muscular dystrophies caused by dysferlin protein deficiency, today announced the signing of a Master Service Agreement with Cellular Dynamics…